Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 3/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15723714 | 0.85 | ESR1 (0.32) | — | |
| SCHEMBL13605208 | 0.82 | PTGS1 (0.38) | KDM4E | |
| SCHEMBL13487955 | 0.78 | KDM4E (0.36) | GRNSORT1KDM4EGAAMAPK14 | |
| SCHEMBL15069896 | 0.78 | GRN (0.35) | GRNSORT1KDM4EGAAMAPK14 | |
| SCHEMBL2609439 | 0.78 | GRN (0.52) | GRNSORT1KDM4EGAAMAPK14 | |
| SCHEMBL23403293 | 0.76 | GRN (0.38) | GRNSORT1KDM4EGAAMAPK14 | |
| SCHEMBL2950904 | 0.76 | KDM4E (0.46) | GRNSORT1KDM4EGAAMAPK14 | |
| SCHEMBL15723866 | 0.76 | GRN (0.34) | GRNSORT1KDM4EGAAMAPK14 | |
| Hydrochloric Acid SCHEMBL1011658 | 0.74 | KDM4E (0.45) | GRNSORT1KDM4EMAPK14 | |
| SCHEMBL5061899 | 0.74 | GRN (0.62) | GRNSORT1KDM4EGAAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | FXR1, SLC10A1, NR1H4 | GRN 4104/4885SORT1 3816/4885KDM4E 4194/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | GRN 3131/4885SORT1 3722/4885KDM4E 4232/4885 |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | GRN 1947/4885SORT1 4514/4885KDM4E 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.